Anzeige
Mehr »
Login
Mittwoch, 19.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Doppeltes “STRONG BUY”! Jetzt bei EAM einsteigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P209 | ISIN: US98943L1070 | Ticker-Symbol:
NASDAQ
18.06.24
21:59 Uhr
4,140 US-Dollar
0,000
0,00 %
1-Jahres-Chart
ZENTALIS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ZENTALIS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ZENTALIS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiUS FDA puts Zentalis' cancer drug studies on partial hold after patient deaths1
DiZentalis Pharma Says FDA Places Partial Clinical Hold On Azenosertib Studies; Stock Down 25.5%1
DiWhy Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?1
DiZentalis Pharma falls as FDA puts cancer therapy trials on hold1
DiZentalis' shares plunge 30% after FDA places WEE1 drug on partial hold over sepsis deaths2
DiUS FDA puts partial clinical hold on Zentalis' cancer drug studies; shares drop3
DiZentalis falls after FDA partial clinical hold on lead asset2
DiZentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program1
04.06.Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)63NEW YORK & SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...
► Artikel lesen
29.05.Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors1
29.05.Zentalis Pharmaceuticals, Inc. - 8-K, Current Report-
23.05.Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting1
14.05.Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit1
07.05.Zentalis Pharmaceuticals GAAP EPS of $0.14, revenue of $40.56M2
07.05.Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
07.05.Zentalis Pharmaceuticals, Inc. - 8-K, Current Report1
01.05.Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)51NEW YORK and SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...
► Artikel lesen
11.04.Zentalis Pharmaceuticals says Melissa Epperly resigns as CFO1
09.04.Zentalis Pharmaceuticals, Inc. - 8-K, Current Report1
02.04.Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 20242
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1